-
Listing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystem更多Seamless listing, trading, clearing and settlement for fixed income
-
Trading
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystem更多
Seamless listing, trading, clearing and settlement for fixed income
-
Clearing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystem更多
Seamless listing, trading, clearing and settlement for fixed income
-
CSD
European CSD modelBuilding the CSD of Choice in Europe更多Euronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)更多The new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperNext generation of indices更多This white paper marks the second edition of Euronext’s Index Outlook series, a recurring publication designed to give investors deeper insight into our index innovation agenda and the structural forces shaping global markets.
-
About Euronext
Abivax
26/06/2015
EnterNext welcomes Abivax on Euronext in Paris
Professor Hartmut Ehrlich, CEO of Abivax, rings the closing bell.
Abivax specializes in the research, development and commercialization of anti-viral drugs and therapeutic vaccines for the treatment of severe infectious diseases.
At the end of 2014, the Group has a portfolio of three products in clinical development: ABX203 (therapeutic vaccine against chronic hepatitis B), ABX464 (new drug against HIV) and ABX196 (adjuvant vaccine against hepatitis B).